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Follicular lymphoma (FL), characterized by a t (14;18)(q32;q21), is one of the most common non-Hodgkinlymphomas (NHL). Although FL is sensitive tochemotherapy, immunotherapy and radiotherapy it
currently remains an incurable disease. The variable outcome of
FL appears to be determined mainly by the tumor-microenviron-
ment and the non-malignant bystander cells.1,2 The immuno-
modulatory drug lenalidomide has been shown to modulate the
production of various cytokines in the tumor-microenvironment
and activates T- and NK-cells.3,4
Impairment of the T-cell immunologic synapse formation in FL
seems to be an active immunosuppressive mechanism, which in
vitro can be overcome by treatment of FL cells with
lenalidomide.5 A synergistic antitumor effect of lenalidomide
and rituximab in lymphoma cell killing has been demonstrated in
mouse models.2,6,7 Additionally, lenalidomide can have a direct
antitumor effect because it inhibits Akt-phosphorylation and
increases p21 expression, which are important for tumor cell
proliferation and survival. The mechanisms of action of
bendamustine include inhibition of the mitotic checkpoints,
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induction of mitotic catastrophe, activation of DNA damage
stress response, intrinsic apoptosis and base-excision DNA repair
mechanisms.8
Several studies have demonstrated clinical activity of lenali-
domide in indolent lymphoma9 and adding rituximab can
improve the response rate with acceptable toxicity.10–12 Inmantle
cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL)
the combination of lenalidomide, bendamustine and rituximab
was found to be effective and feasible in patients in an upfront
setting with a high CR rate but also a high rate of infections.13,14
To date there are no data on the combination of rituximab,
bendamustine and lenalidomide in patients with FL. With this
run-in phase I study we aimed to establish the recommended dose
level (RDL) of bendamustine and lenalidomide for the triplet
combination with rituximab for relapsed or refractory (R/R) FL
patients in a subsequent randomized phase II study.
This is a multicenter, phase I/II study sponsored by HOVON
(Hemato-Oncologie voor Volwassenen Nederland) (HOVON110;
NetherlandsTrialRegister: TrialNL2882; EudraCTnumber: 2011-
000097-56). The study was approved by the Ethics Committee of
the Amsterdam UMC and was conducted in accordance with the
ethical principles of the Declaration of Helsinki.
In the ongoing phase II part, patients are randomized between
arm A (lenalidomide and rituximab) and arm B (lenalidomide,
bendamustine, rituximab). The aim of the phase I part was to
determine the dose limiting toxicity (DLT) and RDL of the
combination of lenalidomide, rituximab and bendamustine in a
28-day schedule in R/R FL patients. Eligible patients were ≥18
years, and were required to have biopsy proven, CD20 positive
stage II-IVR/R FL grade 1–3a.Rituximab refractory cases (defined
as relapse/progression during orwithin 6months after a rituximab
containing regimen) were not eligible. The maximum number of
prior systemic treatment regimens was five. Prior bendamustine
was allowed if it was administered >24 months before enrolment
and had resulted in at least a partial remission (PR).
A 3+3 dose-escalation design was used. Four carefully designed
dose levels were considered: lenalidomide (10mg, 15mg or 20mg)
orally, escalating doses of bendamustine (70mg/m2 or 90mg/m2)
IV, combined with a fixed dose of rituximab (375mg/m2) IV for a
total of 6 induction cycles (Table 1). Patients with complete
remission (CR) or partial remission (PR) continuedwith 2 years of
rituximab maintenance treatment (8 infusions, every 3 months).
When 3 or 6 patients had been enrolled, inclusion was
discontinued until DLT was determined at day 29 of cycle 1.
Patients who died of FL within 29 days of starting treatment
without a DLT were considered non-evaluable and were replaced
by another patient. Dose escalation stopped as soon as at least 2
patients experienced aDLT at the same dose level. Before opening
the next dose level, the DLTs at the preceding dose level were
reviewed. A DLT was defined as ≥ grade 3 non-hematologic
toxicity, grade 4 neutropenia lasting ≥7 days or grade 4
thrombocytopenia (unless due to lymphomatous bone marrow
infiltration), febrile neutropenia, or death of any cause except
lymphoma. For full details of the protocol see Supplement 1
(Supplemental Digital Content, http://links.lww.com/HS/A56).
Patient and treatment characteristics and safety data were
reported per dose level, and were restricted to eligible and
evaluable patients. Adverse events were summarized by the
maximum CTCAE grade per type of AE over a treatment period.
Results of the phase I part will be presented here.
Eighteen patients with R/R FL, from 9 centers in the
Netherlands and 1 in Germany, were enrolled between
November 2011 andMay 2014. Two patients were not evaluable
due to a protocol amendment after inclusion, precluding the
concurrent use of allopurinol during bendamustine treatment,
and one rituximab refractory patient did not fulfill the inclusion
criteria, leaving 15 evaluable patients for determination of the
DLT and RDL. The median age at baseline was 58 years; 60%
were female and the majority of patients had Ann Arbor stage IV
disease (73%). The median number of prior treatments was 1
(range 1–3); 2 were rituximab naïve; none of the patients were
refractory to their last lymphoma therapy (Table 2).
Table 1
Dose Levels of Lenalidomide/Rituximab/Bendamustine for Each Cycle, in Total 6 Induction Cycles.
Agent Level 1 (N=3) Level 2 (N=3) Level 3 (N=3) Level 4 (N=6) Route of administration and days
Lenalidomide 10mg o.d. 15mg o.d. 15mg o.d. 20mg o.d. p.o. day 3-21
Rituximab 375 mg/m2
(max 800 mg) o.d.
375 mg/m2
(max 800 mg) o.d.
375 mg/m2
(max 800 mg) o.d.
375 mg/m2
(max 800 mg) o.d.
i.v. day 1
Bendamustine 70 mg/m2
(max 150 mg/day) o.d.
70 mg/m2
(max 150 mg/day) o.d.
90 mg/m2
(max 150 mg/day) o.d.
90 mg/m2
(max 150 mg/day) o.d.
i.v. day 1–2
Table 2
Demographic and Disease Characteristics of the 15 Patients
Enrolled in the Phase I Study.
Total number 15
Age




Stage II 2 (13%)
Stage III 2 (13%)












R-CHOP (+/ RT) 4
CVP 2
R-CVP (+/ RT) 9
Chlorambucil 2
Fludarabine 1
Rituximab during prior treatment 13 (87%)
Stem cell transplantation 1 (7%)
Response to last line of treatment
Complete response (CR) 9 (60%)
Complete response, unconfirmed (CRu) 1 (7%)
Partial response (PR) 4 (27%)
Unknown 1 (7%)
∗
Patients could have had more than 1 systemic regime prior to start of the study.
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Among all 15 eligible patients only 1 DLT occurred before day
29 of cycle 1. This event, a grade 3 allergic reaction probably due
to bendamustine, occurred at dose level 4 (the highest dose level).
One other patient discontinued the study after cycle 4, because of
an allergic reaction to rituximab. Despite recommendations
against the use of allopurinol, two patients, 1 in dose level 2 and 1
in dose level 3, used allopurinol; none of them experienced any
signs of Stevens-Johnsons syndrome.
All patients experienced at least 1 AE grade 2–4, in total 57
AEs were reported; 65% (n=37 grade 2, 24% (n=14) grade 3
and 10% (n=6) grade 4. The most common AEs of any grade
were: neutropenia, leucocytopenia, gastrointestinal disorders,
infections, and abnormal laboratory results (Table 3). Six
patients (40%) experienced a total of 13 SAEs; 3 pneumonias, 2
allergic reactions and 5 second primary malignancies; 3 basal
cell carcinoma, 1Merkel cell carcinoma, and 1 lung cancer. The
lung cancer was only located in the lung and treated with
curative intended radiotherapy. The other SAEs occurred only
once; fever, knee pain and thrombocytopenia. Eight were
classified as SAEs due to hospitalization, all 13 SAE’s resolved
completely.
This first clinical study investigating the combination of
lenalidomide, bendamustine and rituximab in R/R FL showed an
acceptable safety and tolerability profile. Only one DLT was
reported and most AEs were grade 2. Hematological toxicity was
mostly seen at dose level 4 without severe consequences. The
secondary primary malignancies were considered possibly
related, but the patients had received prior therapy that could
have contributed. We concluded that dose level 4 (lenalidomide
20mg dag 3–21 day, bendamustine 90mg/m2 day 1–2, combined
with rituximab 375mg/m2 day 1) is feasible for R/R FL patients.
This dose level is currently being studied further in the
randomized phase II part of the study for efficacy and toxicity
in comparison with 6 cycles of lenalidomide 20mg dag 1 to 21
day and rituximab 375mg/m2 day 1.
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Table 3
Maximum Grade of the Adverse Events During the Induction Treatment.
Level 1 (n=3) Level 2 (n=3) Level 3 (n=3) Level 4 (n=6) Treated set (n=15)
Grade 2 Grade 3 Grade 2 Grade 3 Grade 2 Grade 3 Grade 2 Grade 3 Grade 4 Grade 2–4
Any AE 2 (67%) 1 (33%) 1 (33%) 2 (67%) 1 (33%) 2 (67%) 2 (33%) 4 (67%) 15 (100%)
Neutropenia 1 (33%) 1 (33%) 2 (67%) 1 (17%) 2 (33%) 3 (50%) 10 (67%)
Leucocytopenia 1 (33%) 1 (33%) 1 (33%) 2 (33%) 2 (33%) 1 (17%) 8 (53%)
Gastrointestinal disorders 2 (67%) 2 (67%) 1 (17%) 5 (33%)
Infection 2 (67%) 2 (33% 1 (17%) 5 (33%)
Abnormal laboratory results 1 (33%) 1 (33%) 1 (33%) 1 (33%) 1 (17%) 5 (33%)
Infusion related reactions 1 (33%) 2 (67%) 1 (17%) 4 (27%)
Eye disorders 2 (67%) 1 (33%) 3 (20%)
Rash 1 (33%) 1 (17%) 1 (17%) 3 (20%)
Vascular disorders 1 (33%) 1 (33%) 1 (17%) 3 (20%)
Allergic reaction 1 (33%) 1 (17%) 2 (13%)
Nervous system disorders 2 (33%) 2 (13%)
Anemia 2 (33%) 2 (13%)
Thrombocytopenia 1 (17%) 1 (7%)
Cough 1 (33%) 1 (7%)
External ear inflammation 1 (33%) 1 (7%)
Back pain 1 (33%) 1 (7%)
Anxiety 1 (33%) 1 (7%)
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